A. McGovern

First name

A.

Middle name

P.

Last name

McGovern

Dennis, J. M., Young, K. G., McGovern, A. P., Mateen, B. A., Vollmer, S. J., Simpson, M. D., et al. (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1

View

Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., et al. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687

View

McGovern, A. P., Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., & Jones, A. G. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8

View

McGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., et al. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238

View

Farmer, R. E., Beard, I., Raza, S. I., Gollop, N. D., Patel, N., Tebboth, A., et al. (2021). Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: a Descriptive Analysis in the UK CPRD. Clin Ther. http://doi.org/10.1016/j.clinthera.2020.12.015

View